Yoshiyuki Kakehi

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

Meelan Bul, Xiaoye Zhu, R. Valdagni et al. · European Urology · 2012 · 534 citations

Urology, Cancer Epidemiology, Cancer Screening +9

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 383 citations · Full text

Era 223, Urology, Medicine +8

A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment

Leonard P. Bokhorst, R. Valdagni, Antti Rannikko et al. · European Urology · 2016 · 381 citations · Full text

Epidemiological Trend, Prias Study, Preventive Medicine +11

Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.

Hiroya Oka, Yuji Chatani, Rika Hoshino et al. · PubMed · 1995 · 301 citations

Renal Pathology, Mapk Cascade, Cancer Biology +18

Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.

Hiroshi Maéda, Seiji Hori, Hideki Nishitoh et al. · PubMed · 2001 · 197 citations

Apoptosis, Cell Death, Cancer Biology +17